NCT05936229 - Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Biotech Hunter

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions

Recurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

Interventions

BIOLOGICAL

Interferon Beta-1A

Given IV

PROCEDURE

X-Ray Imaging

Undergo x-ray

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Lumbar Puncture

Undergo LP

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Biospecimen Collection

Undergo blood and CSF sample collection

PROCEDURE

Biopsy

Undergo tissue biopsy

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle